Research advances in adiponectin actions in nonalcoholic fatty liver disease
-
摘要:
非酒精性脂肪性肝病(NAFLD)的发病率呈逐年上升及年轻化的趋势。目前对该病缺乏有效的治疗方法,对其发病的确切机制也尚未完全阐明。近年来的研究认为,脂肪细胞因子脂联素(APN)具有肝脏保护作用,与NAFLD发生有着密切关系,已成为国内外研究的热点。概述了APN在NAFLD中的作用机制,APN与非酒精性脂肪性肝炎(NASH)及NAFLD相关肝纤维化的相关性及临床研究概况。认为APN有望成为NAFLD靶向治疗药物,深入研究APN信号传导通路更好地理解APN调控机制,将为NAFLD的防治提供新的策略。
Abstract:The incidence of nonalcoholic fatty liver disease( NAFLD) is increasing worldwide and the age of onset gradually gets younger.However,specific therapeutic interventions are lacking. The exact mechanism of NAFLD has not yet been well elucidated. Recent studies indicate that adiponectin( APN) is an adipokine with anti- inflammatory activity and is considered a hepatic protector,which plays a central role in the pathogenesis of NAFLD. Research on APN actions in NAFLD is popular around the world. This article summarizes the mechanism of APN actions in NAFLD,briefly describes the relationship of APN with nonalcoholic steatohepatitis and NAFLD- related hepatic fibrosis,and reviews related clinical studies. It is suggested that APN holds promise as a novel therapeutic target in the treatment of NAFLD and further research into the signaling pathway of APN would lead to a better understanding of its action mechanism and can provide a novel strategy for the treatment of NAFLD.
-
Key words:
- fatty liver /
- adiponectin /
- liver cirrhosis /
- targeted therapy /
- review
计量
- 文章访问数: 2414
- HTML全文浏览量: 12
- PDF下载量: 450
- 被引次数: 0